Novel therapeutic concept
With our proprietary discovery platform, we are developing a pipeline of first-in-class, safe and effective therapeutics for autoimmune diseases with high unmet medical need.
Our unique therapeutic approach consists of targeting the IGFBP3/TMEM219 axis and its dysregulation to re-establish organ function in patients suffering from autoimmune disorders where elevated levels of IGFBP3 have been found.
Our platform delivers an expanding library of monoclonal antibodies (mAbs) and fusion proteins capable of abrogating the binding capability of IGFBP3 to its receptor, TMEM219, therefore inhibiting apoptosis and restoring cell and organ function in affected patients.
Our current focus is the in-house development of two clinical candidates as first-in-class therapeutics that disrupt the pathway to stop disease progression and revert the outcome of T1D and IBD.